Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway

Cell Proliferation

Volumn 46, Issue 4, 2013, Pages 436-446

  Luo, X ^a   Dong, Z ^a   Chen, Y ^a   Yang, L ^a   Lai, D ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BREAST CANCER RESISTANCE PROTEIN; MICRORNA 200C; MICRORNA 20A; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; VIMENTIN;

ADHERENT CELL; ADULT; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL ASSAY; CELL CYCLE; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; COLONY FORMATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FLOW CYTOMETRY; GENE ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALIGNANT TRANSFORMATION; MESENCHYMAL STEM CELL; METASTASIS; OVARY CARCINOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPHEROID CELL; SUSPENSION CELL CULTURE; UPREGULATION; WESTERN BLOTTING;

CELL DIFFERENTIATION; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MICRORNAS; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SPHEROIDS, CELLULAR;

EID: 84880668080     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/cpr.12038     Document Type: Article

References (44)

1. Schwartz PE (2002) Current diagnosis and treatment modalities for ovarian cancer. Cancer Treat. Res. 107, 99-118.
2. Torri V, Harper PG, Colombo N, Sandercock J, Parmar MK (2000) Paclitaxel and cisplatin in ovarian cancer. J. Clin. Oncol. 18, 2349-2351.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J. Clin. 61, 69-90.
4. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730-737.
5. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100, 3983-3988.
6. Uchida N, Buck DW, He D, Reitsma MJ, Masek M, Phan TV et al. (2000) Direct isolation of human central nervous system stem cells. Proc. Natl. Acad. Sci. USA 97, 14720-14725.
7. Rizzo S, Attard G, Hudson DL (2005) Prostate epithelial stem cells. Cell Prolif. 38, 363-374.
8. Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890.
9. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715.
10. Gort EH, van Haaften G, Verlaan I, Groot AJ, Plasterk RH, Shvarts A et al. (2008) The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2alpha. Oncogene 27, 1501-1510.
11. Yilmaz M, Christofori G (2009) EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 28, 15-33.
12. Cao L, Shao M, Schilder J, Guise T, Mohammad KS, Matei D (2012) Tissue transglutaminase links TGF-beta, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene 31, 2521-2534.
13. Hutvagner G, Zamore PD (2002) A microRNA in a multiple-turnover RNAi enzyme complex. Science 297, 2056-2060.
14. Olson P, Lu J, Zhang H, Shai A, Chun MG, Wang Y et al. (2009) MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev. 23, 2152-2165.
15. Fu X, Tian J, Zhang L, Chen Y, Hao Q (2012) Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett. 586, 1279-1286.
16. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J et al. (2008) MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 68, 425-433.
17. Blanco-Aparicio C, Renner O, Leal JF, Carnero A (2007) PTEN, more than the AKT pathway. Carcinogenesis 28, 1379-1386.
18. Iliopoulos D, Polytarchou C, Hatziapostolou M, Kottakis F, Maroulakou IG, Struhl K et al. (2009) MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci. Signal. 2, ra62.
19. Irie HY, Pearline RV, Grueneberg D, Hsia M, Ravichandran P, Kothari N et al. (2005) Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J. Cell Biol. 171, 1023-1034.
20. Liu T, Cheng W, Lai D, Huang Y, Guo L (2010) Characterization of primary ovarian cancer cells in different culture systems. Oncol. Rep. 23, 1277-1284.
21. Ma L, Lai D, Liu T, Cheng W, Guo L (2010) Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3. Acta Biochim. Biophys. Sin. (Shanghai) 42, 593-602.
22. Zhang J, Du YY, Lin YF, Chen YT, Yang L, Wang HJ et al. (2008) The cell growth suppressor, mir-126, targets IRS-1. Biochem. Biophys. Res. Commun. 377, 136-140.
23. Arai F, Suda T (2007) Maintenance of quiescent hematopoietic stem cells in the osteoblastic niche. Ann. N. Y. Acad. Sci. 1106, 41-53.
24. Orford KW, Scadden DT (2008) Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. Nat. Rev. Genet. 9, 115-128.
25. Berx G, Raspe E, Christofori G, Thiery JP, Sleeman JP (2007) Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Clin. Exp. Metastasis 24, 587-597.
26. Bapat SA, Mali AM, Koppikar CB, Kurrey NK (2005) Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 65, 3025-3029.
27. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R et al. (2006) Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc. Natl. Acad. Sci. USA 103, 11154-11159.
28. Elloul S, Elstrand MB, Nesland JM, Trope CG, Kvalheim G, Goldberg I et al. (2005) Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer 103, 1631-1643.
29. Christiansen JJ, Rajasekaran AK (2006) Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res. 66, 8319-8326.
30. Strauss R, Li ZY, Liu Y, Beyer I, Persson J, Sova P et al. (2011) Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One 6, e16186.
31. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T (2005) Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat. Rev. Cancer 5, 744-749.
32. Turley EA, Veiseh M, Radisky DC, Bissell MJ (2008) Mechanisms of disease: epithelial-mesenchymal transition - does cellular plasticity fuel neoplastic progression? Nat. Clin. Pract. Oncol. 5, 280-290.
33. Drasin DJ, Robin TP, Ford HL (2011) Breast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticity. Breast Cancer Res. 13, 226.
34. Lee JM, Dedhar S, Kalluri R, Thompson EW (2006) The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J. Cell Biol. 172, 973-981.
35. Cho EY, Choi Y, Chae SW, Sohn JH, Ahn GH (2006) Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms. Pathol. Int. 56, 62-70.
36. Voutilainen KA, Anttila MA, Sillanpaa SM, Ropponen KM, Saarikoski SV, Juhola MT et al. (2006) Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer. J. Clin. Pathol. 59, 460-467.
37. Li J, Zhou BP. (2011) Activation of β-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer 11, 49. doi: 10.1186/1471-2407-11-49.
38. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T (2007) MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133, 647-658.
39. Gwak HS, Kim TH, Jo GH, Kim YJ, Kwak HJ, Kim JH et al. (2012) Silencing of microRNA-21 confers radio-sensitivity through inhibition of the PI3K/AKT pathway and enhancing autophagy in malignant glioma cell lines. PLoS One 7, e47449.
40. Yin G, Chen R, Alvero AB, Fu HH, Holmberg J, Glackin C et al. (2010) TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene 29, 3545-3553.
41. Fan X, Liu Y, Jiang J, Ma Z, Wu H, Liu T et al. (2010) miR-20a promotes proliferation and invasion by targeting APP in human ovarian cancer cells. Acta Biochim. Biophys. Sin. (Shanghai) 42, 318-324.
42. Cochrane DR, Howe EN, Spoelstra NS, Richer JK (2010) Loss of miR-200c: a marker of aggressiveness and chemoresistance in female reproductive cancers. J Oncol. 2010, 821717.
43. Qian S, Ding JY, Xie R, An JH, Ao XJ, Zhao ZG et al. (2008) MicroRNA expression profile of bronchioalveolar stem cells from mouse lung. Biochem. Biophys. Res. Commun. 377, 668-673.
44. Gorelik E, Lokshin A, Levina V (2010) Lung cancer stem cells as a target for therapy. Anticancer Agents Med. Chem. 10, 164-171.